emitefur has been researched along with fluorouracil in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 20 (74.07) | 18.2507 |
| 2000's | 5 (18.52) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, S; Fukushima, M; Imaoka, T; Kimura, A; Kimura, Y; Ohshimo, H; Shimamoto, Y; Shirasaka, T; Utsunomiya, T | 1 |
| Fujii, S; Fujita, F; Fujita, M; Fukushima, M; Shirasaka, T; Taguchi, T | 1 |
| Fujii, S; Fukushima, M; Imaoka, T; Ohshimo, H; Shimamoto, Y; Shirasaka, T | 1 |
| Fujii, S | 1 |
| Asakawa, M; Fujii, M; Fukuoka, M; Furuse, K; Nakai, Y; Niitani, H; Ohta, M; Yamaguchi, Y; Yoshida, K | 1 |
| Ichihara, N; Imaoka, T; Miyauchi, S; Motoyama, M | 1 |
| Fujita, F; Fujita, M; Sakamoto, Y | 1 |
| Hayashi, K; Imaoka, T; Kawaguchi, T; Kubo, M; Matsui, Y; Miyauchi, S; Utsunomiya, T | 1 |
| Awogi, T; Itoh, T; Kaneko, E; Kirkland, DJ; Marshall, RR; Shibahara, T; Takahashi, N; Tsushimoto, G | 1 |
| Fujita, F; Fujita, M; Sakamoto, Y; Taguchi, T | 1 |
| Taguchi, T | 1 |
| Fujita, F; Fujita, M; Inaba, H; Taguchi, T | 1 |
| Hiraoka, M; Hirohashi, M; Miyauchi, S; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Takagi, T | 1 |
| Akiyama, H; Imaoka, T; Kawaguchi, T; Miyauchi, S; Motoyama, M; Odomi, M; Okada, T | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Kobayashi, K | 1 |
| Hirohashi, M; Miyauchi, S; Murata, R; Oya, N; Sasai, K; Shibamoto, Y; Shibata, T; Takagi, T; Takahashi, M | 1 |
| Sasaki, T | 1 |
| Osaki, T; Ueta, E; Yamamoto, T; Yoneda, K | 1 |
| Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH | 1 |
| Diasio, RB | 2 |
| Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M | 1 |
| Corey, A; Eager, R; Hoff, PM; Nemunaitis, J; Pazdur, R; Sekar, K; Thompson, J; Tkaczuk, K; Twaddell, T | 1 |
| Maehara, Y; Sugimachi, K | 1 |
| Hoff, PM; Saad, ED | 1 |
| Eng, C; Kindler, HL; Schilsky, RL | 1 |
10 review(s) available for emitefur and fluorouracil
| Article | Year |
|---|---|
[Development of fluorinated pyrimidines in Japan].
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorodeoxyuridylate; Fluorouracil; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Oxonic Acid; Pyridines; Rats; Tegafur | 1993 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
[Clinical use of platinum compounds and fluorinated pyrimidines for lung cancer].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Drug Combinations; Fluorouracil; Humans; Lung Neoplasms; Tegafur; Uracil | 1996 |
[New anti-cancer drugs for gastrointestinal cancers].
Topics: Amino Acids; Antidotes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferons; Irinotecan; Leucovorin; Paclitaxel; Taxoids | 1997 |
Fluoropyrimidines: a critical evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Leucovorin; Oxonic Acid; Pyridines; Tegafur; Uracil | 1999 |
Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Dihydrouracil Dehydrogenase (NADP); Drug Evaluation; Enzyme Inhibitors; Fluorouracil; Humans; Neoplasms; Oxidoreductases; Tegafur; Uracil | 1999 |
Oral fluoropoyrimidines.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Enzyme Inhibitors; Fluorouracil; Folic Acid Antagonists; Humans; Leucovorin; Oxidoreductases; Oxonic Acid; Prodrugs; Pyridines; Tegafur; Uracil | 1999 |
Oral DPD-inhibitory fluoropyrimidine drugs.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Drug Resistance, Neoplasm; Fluorouracil; Humans; Leucovorin; Oxidoreductases; Oxonic Acid; Pyridines; Tegafur; Uracil | 2000 |
Other fluorinated pyrimidines in the treatment of solid tumors.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Drug Combinations; Fluorouracil; Humans; Neoplasms; Oxonic Acid; Pyridines; Tegafur | 2001 |
Oral fluoropyrimidine treatment of colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Patient Compliance; Prodrugs; Pyridines; Tegafur; Treatment Outcome | 2001 |
3 trial(s) available for emitefur and fluorouracil
| Article | Year |
|---|---|
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Thrombocytopenia; Vomiting | 1994 |
Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms | 2000 |
A phase II trial of a new 5-fluorouracil derivative, BOF-A2 (Emitefur), for patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2000 |
14 other study(ies) available for emitefur and fluorouracil
| Article | Year |
|---|---|
[Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
Topics: Animals; Antineoplastic Agents; Female; Fluorouracil; Male; Mammary Neoplasms, Experimental; Mice; Neoplasms, Experimental; Rats | 1990 |
[Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Liver; Mice; Mice, Nude; Microsomes; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Stomach Neoplasms | 1990 |
Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Fluorouracil; Mice; Mice, Inbred ICR; Pyridines; Rats; Sarcoma 180; Sarcoma, Yoshida | 1989 |
[BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Floxuridine; Fluorouracil; Liver; Mice; Pyridines; Pyrimidines; Rats; Sarcoma 180; Sarcoma, Experimental; Sarcoma, Yoshida; Tegafur; Uracil | 1987 |
[Effect of BOF-A2 on experimental and spontaneous metastasis model of mouse colon 26].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation | 1994 |
[Combination chemotherapy of BOF-A2, a new 5-FU derivative, with various anticancer agents against human cancer xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Interferon-alpha; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Neoplasm Transplantation; Transplantation, Heterologous | 1994 |
Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Combinations; Drug Interactions; Fluorouracil; Lung; Lung Neoplasms; Male; Neoplasm Transplantation; Pyridines; Rats; Sarcoma, Yoshida; Tegafur; Transplantation, Heterologous; Uracil | 1994 |
Mutagenic and clastogenic properties of (3-[3-(6-benzoyloxy-3-cyano-2- pyridyloxycarbonyl) benzoyl]-1-ethoxymethyl-5-fluorouracil) (BOF-A2), a new 5-fluorouracil derivative with anti-tumour activity.
Topics: Animals; Antineoplastic Agents; Bone Marrow; CHO Cells; Chromosome Aberrations; Cricetinae; Escherichia coli; Fluorouracil; In Vitro Techniques; Mice; Micronucleus Tests; Mutagenicity Tests; Mutagens; Rats; Salmonella typhimurium | 1993 |
[Antitumor activity of combination treatment of BOF-A2 with CDDP against human lung cancers xenografted in nude mice].
Topics: Adenocarcinoma, Papillary; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 1993 |
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Stomach Neoplasms; Tegafur; Uracil | 1993 |
The combined antitumour effect of a new 5-fluorouracil derivative, BOF-A2, and radiation in vivo.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Mice; Mice, Inbred C3H; Neoplasms, Experimental | 1996 |
Leukopenia-inducing effect of a combination of a new 5-fluorouracil (5-FU)-derived drug, BOF-A2 (emitefur), with other 5-FU-derived drugs or BV-araU (sorivudine) in rats.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Arabinofuranosyluracil; Dose-Response Relationship, Drug; Drug Combinations; Fluorouracil; Leukopenia; Male; Rats; Rats, Sprague-Dawley | 1996 |
Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Tumor Stem Cell Assay | 1996 |
The inhibitory action of BOF-A2, a 5-fluorouracil derivative, on squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; DNA, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Proliferating Cell Nuclear Antigen | 1999 |